Pirarubicin
- Generic Name
- Pirarubicin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C32H37NO12
- CAS Number
- 72496-41-4
- Unique Ingredient Identifier
- D58G680W0G
- Associated Conditions
- -
- Associated Therapies
- -
Trilaciclib Combing Chemotherapy in the Neoadjuvant Treatment of Osteosarcoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-12-03
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Peking University People's Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06714383
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
Not Applicable
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-03-18
- Last Posted Date
- 2022-03-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 500
- Registration Number
- NCT05287308
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
Combination Therapy of Anthracyclines for Children With Nephroblastoma
Phase 4
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03892330
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2017-11-14
- Last Posted Date
- 2020-05-19
- Lead Sponsor
- Peking University People's Hospital
- Registration Number
- NCT03342300
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, China
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients
Phase 2
- Conditions
- Interventions
- First Posted Date
- 2016-10-04
- Last Posted Date
- 2016-11-17
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02923557
- Locations
- 🇨🇳
Peking University Frist Hospital, Beijing, Beijing, China
Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients
- First Posted Date
- 2016-04-15
- Last Posted Date
- 2017-09-21
- Lead Sponsor
- Peking University First Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT02740426
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
Comparative Analysis of the Efficacies in Neoadjuvant Chemotherapy of Breast Cancer
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2015-11-24
- Lead Sponsor
- 307 Hospital of PLA
- Target Recruit Count
- 104
- Registration Number
- NCT02613026
- Locations
- 🇨🇳
The fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China
🇨🇳Hunan Provincial People's Hospital, Changsha, Hunan, China
🇨🇳Xiangya Hospital, Central South University, Changsha, Hunan, China
Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma
Phase 2
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Guangxi Medical University
- Registration Number
- NCT02585479
Applying Pediatric Regimens to Younger Adult Patients With Acute Lymphoblastic Leukemia (ALL)
- First Posted Date
- 2005-08-17
- Last Posted Date
- 2008-11-14
- Lead Sponsor
- Japan Adult Leukemia Study Group
- Target Recruit Count
- 120
- Registration Number
- NCT00131053
- Locations
- 🇯🇵
Department of Hematology, Nagoya University Graduate School of Medicine, Nagoya, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath